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Background: Patients with non ST elevationmyocardial infarction
are a very heterogenous population, with varying risks of early
and long term adverse events. Early risk stratification at admis-
sion seems to be essential for planning therapeutic strat-
egy.Several groups have developed comprehensive risk scores
that use clinical variables which include TIMI, PURSUIT, GRACE
and syntax risk score. In this study we sought to compare these
risk scores in a Indian NSTEMI cohort.
Methods and result: This is a prospective cohort study. A total 213
patients with NSTEMI were included in this study. The mean age
of the cohort was 61 ± 12 years. For earlymortality all three RS had
good discriminative accuracy. Again the GRACE RS is better (AUC
e 0.824 CI: 0.69 e 0.95) as compared to TIMI or PURSUIT RS. GRACE
RS also has a good sensitivity, specificity and negative predictive
value and hence has better predictive accuracy when compared to
TIMI and PURSUIT RS. In longterm (1year) mortality all the RSs
have a good discriminative accuracy with GRACE having a higher
AUC of 0.778 CI: 0.69 e 0.86. All the risk scores have a good pre-
dictive accuracy for long term events and mortality. Early mor-
tality in this group shows syntax to have a better discriminative
accuracy (AUC e 0.885 CI: 0.78 e 0.98) than the other risk scores.
After logistic regression, the predictors of early mortality were
CCS class IV, low systolic and low diastolic blood pressure. For the
longterm mortality the predictors were age, low systolic and dia-
stolic blood pressure, low ejection fraction, low haemoglobin, high
serum creatinine and cardiac failure during hospital stay.
Conclusions: The three scores have good discriminative accuracy
and predictive accuracy for both short e term and long term
events and mortality in Indian population. The GRACE risk score
has better AUC at both the early and 1-year prognostication.
Diastolic blood pressure, echocardiographic variables like regional
wall motion abnormalities, ejection fraction and haemoglobin are
significant prognostic variables in Indian population.
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Background: By 2015, India will have the largest coronary artery
disease (CAD) burden in the world. Indians manifest CAD at a
younger age. Inflammation plays a key role in CAD progression.
Inflammatory marker high sensitivity C-reactive protein (hsCRP)
predicts CAD risk either by correlation with CAD extent (disease
marker) or as an indicator of inflammatory event that leads to
plaque rupture (a process marker).
Aim: To assess the role of vascular inflammation and correlate
with coronary atherosclerosis in an economically and relevant
section of population of young Indians.
Methods: Serum hs-CRP (measured by immune-turbidimetry
technique) level was measured in young adults (18e45 years) with
angiographic proven CAD (60 patients), and compared with those
>45 years age (24 patients), and in controls with no CAD (14
patients).Later, the levels of hs-CRP were compared with the
angiographic stenosis and extent score in young CAD patients.
Results: Mean hsCRP was elevated in Young CAD patients more
than in those of Old CAD patients and Controls, and this trendwas
found to be significant by ANOVA (P ¼ 0.028).The hs-CRP levels
were found to be in direct proportion to both stenosis and extent
score of coronary artery disease (P < 0.01) in young adults.
Conclusion: Serum hs-CRP levels and inflammation have a posi-
tive correlation with the disease burden in the young CAD patient.
Premature CAD in Young Asian Indians could be partly explained
by increased vascular inflammation. Further studies and in-
terventions to identify & reduce risk factors in an economically
and socially relevant section of population of a fast developing
country like India is urgently needed.
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Background: ST elevated myocardial infarction is a serious and
life threatening condition. In patients suitable for thrombolytic
treatment, time is critical and reperfusion should be initiated as
soon as possible. Reteplase is commonly used in themanagement
of ST elevated myocardial infarction.
Objective: To assess the safety and efficacy of intravenous Retelex
(Reteplase) injection in management of patients with ST elevated
myocardial infarction in clinical practice.
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Material and Methods: An open label, non-comparative, multi-
centric, post marketing observational study was conducted in >18
years of patients with ST elevated myocardial infarction (STEMI)
receiving Retelex. All patients received 20 units Retelex within 6
hours after the onset of acute myocardial infarction (AMI) symp-
toms. The dose was given as two 10 unit Intravenous injections
each over two minutes 30 minutes apart.
Evaluation criteria: Patients were followed on day 1, 3, 5/7 and 30.
The primary evaluation criteria was total number of patients
showing clinically successful thrombolysis based on 50% resolu-
tion of ST-elevation in the maximum affected ( adjacent) leads
within 90e120 minutes of initiation of Reteplase and resolution of
chest pain. Secondary evaluation criteria included LV function by
2D echo after 24 hrs and within 7 days after thrombolysis, per-
centage of patient requiring rescue PCI, percentage of patient
underwent angioplasty or CABG after thrombolysis. Door to nee-
dle time was also recorded in patients receiving the study drug.
Global assessment of efficacy and safety was done by patient as
well as investigator. All adverse events were recorded for safety
assessment.
Results: A total of 228 patients were enrolled out of which 140
were having diabetes mellitus. Out of all patients, 68.9% had ST
elevated anterior wall myocardial infarction. Resolution of 50% of
ST elevation and resolution of chest pain was reported in 90.50%
and 95.4% patients respectively. ). No significant difference was
seen in primary efficacy variables between diabetes versus non-
diabetes patients (p ¼ 0.1538 for 50% ST elevation resolution, p ¼
0.4031 resolution of chest pain). Themean LV function by 2 D echo
after 24 hours and within 7 days after thrombolysis was 46.79
(+9.33). Rescue PCI was required by 7.6 % patients while angio-
plasty and CABGwas done in 22% and 16.8% patients respectively.
No significant difference was seen in diabetes versus non-dia-
betes patients requiring rescue PCI (p ¼ 0.1059), angioplasty (p ¼
0.2172) and CABG (p ¼ 0.9128). The incidence of adverse event in
this study was 5.3%.
Conclusion: Reteplase IV Injection-recombinant plasminogen
activator is effective and well tolerated in the management of ST
elevated myocardial infarction (STEMI) in Indian patients
including diabetes patients.
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Background: The association between overt hypothyroidism and
coronary artery disease has been often observed in many studies.
Less evident is the data on asymptomatic hypothyroidismwithout
clinical manifestations and with mild elevation of thyroid stim-
ulating hormone.
Methods: It is a prospective observational study of about 1200
patients with Ischemic heart disease. 240(20%) patients were
observed to have Hypothyroidism. Consecutive 75 (31.25%) pa-
tients with hypothyroidism and ischemic heart disease was
analyzed for the present study.
Results: Incidence of Hypothyroid patients among 1200 Ischemic
Heart Disease patients who were admitted in our centre during a
period of 18 months from 1st August 2012 after satisfying the
exclusion criteria was 75(6.25%) 31 males & 24 females. Newly
detected cases of hypothyroidism was 22(29.3%)13 males & 9 fe-
males, of which 12 patients was diagnosed as subclinical hypo-
thyroidism and was initiated treatment and self reported cases of
Hypothyroidism was 53(70.6%) 27 males & 26 females.
Out of the 22 newly reported cases of Hypothyroidism 14(63.6%)
patients had elevated levels of total cholesterol(>200 mg/dL),
LDL(>150), HDL(<40 mg/dL, triglycerides(>150mg/dL) for which
statin therapy was initiated and 5 (22.7%) patients was on statin
therapy for dyslipidemia with normal levels of lipid profile and
with average statin dose of 20 mg daily. 3 patients had normal
values of total cholesterol, LDL, HDL, triglycerides.
Site of coronary artery lesion in self reported case of hypothy-
roidism in ischemic heart disease patients was LAD-32.08%, LCX-
26.42%, RCA-15.09%, and others-3.77%. Site of coronary artery
lesion in newly detected case of hypothyroidism in ischemic heart
disease patients was LAD-40.91%, RCA-22.73, LCX-13.64% and
others-4.55%. PTCA was done in 78.7%% of the patient under
study, medical management and follow up initiated in 18.7% and
CABG in 2.6% patients.
Conclusion: The incidence of hypothyroidism among our study
populationwith ischemic heart diseasewas 6.25%. In self reported
cases of reported cases of Hypothyroidism, 43.4% of patients was
on stain therapy for Dyslipidemia and 30.18% patients was diag-
nosed as new cases of Dyslipidemia. In newly reported cases of
hypothyroidism 63.6% patients was diagnosed as new cases of
Dyslipidemia. LAD lesion(44%) was dominating in both self re-
ported and newly detected cases of hypothyroidismwith ischemic
heart disease.
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Background: High levels of mean platelet volume (MPV) may be
associated with adverse outcomes in patients with myocardial
infarction (MI). We examined the association between MPV and
the risk of death and adverse cardiovascular outcomes in patients
with MI.
Methods: We studied consecutive patients with MI admitted to a
tertiary care hospital during a period of 1year. MPV was measured
at admission and at third month. Patients were followed-up for
one-year primary composite outcome of cardiovascular death,
stroke, fatal or nonfatal MI and cardiac failure. Patients were
classified according to tertile of baseline MPV.
Results: A total of 1206 MI patients, including 934 males (77.4%)
and 272 females (22.6%) were studied. The mean age of the study
population was 55.93 ± 11.07 years. At one-year follow-up, 292
(28.57%) primary outcome occurred: cardiovascular mortality 78
(7.6%), fatal or nonfatal MI 153 (15.0%), stroke 30 (2.9%), and car-
diac failure 128 (12.52%). Highest tertile MPV patients had higher
primary outcome as compared with those with MPV in the lowest
tertile (adjusted OR ¼ 1.70; 95% CI: 1.18 to 2.45; p ¼ 0.01). Total
mortality was also more in high MPV group (adjusted OR 2.83; 95%
CI: 1.49 to 5.35; p < 0.001). There were no significant changes in
meanMPV values at admission from those at thirdmonth interval
(9.15 ± 0.99 Vs 9.19 ± 0.94; p ¼ 0.2).
i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) s 1es 1 4 3S2
